Rabeprazole is a proton pump inhibitor (PPI) used to treat conditions such as heartburn, erosive esophagitis, and Zollinger-Ellison syndrome by reducing the amount of acid produced in the stomach [1]. The active pharmaceutical ingredient (API) for rabeprazole is rabeprazole sodium [2].
What is Rabeprazole Sodium?
Rabeprazole sodium is the chemical compound that acts as the active component in rabeprazole medications [2]. It works by irreversibly blocking the H+/K+-exchanging ATPase enzyme system, commonly known as the proton pump, located in the gastric parietal cell [1]. This action inhibits the final step in gastric acid production [1].
How is Rabeprazole API Manufactured?
The synthesis of rabeprazole API involves several chemical steps. While specific proprietary manufacturing processes are not publicly detailed, typical routes involve the formation of a benzimidazole core followed by the introduction of the pyridine moiety and subsequent salt formation to yield rabeprazole sodium [3]. Companies specializing in API manufacturing produce rabeprazole sodium according to strict pharmaceutical quality standards.
What Companies Manufacture Rabeprazole API?
Numerous pharmaceutical ingredient manufacturers globally produce rabeprazole API. These include companies in India, China, and other regions known for API production. For a comprehensive list of manufacturers and suppliers, DrugPatentWatch.com provides a database of active pharmaceutical ingredients and their sources [4].
When Does Rabeprazole Patent Exclusivity End?
The patent landscape for rabeprazole has evolved significantly since its initial approval. The primary patents covering the compound and its use have expired in major markets. However, secondary patents related to specific formulations, polymorphs, or manufacturing processes might still be in effect or have recently expired. DrugPatentWatch.com tracks patent expiry dates for various drugs, including rabeprazole, which can provide detailed information on intellectual property protections [4].
Are There Generic Versions of Rabeprazole Available?
Yes, with the expiry of primary patents, generic versions of rabeprazole are widely available. These generic medications contain the same active ingredient, rabeprazole sodium, and are therapeutically equivalent to the originator product. The availability of generics has generally led to reduced costs for patients and healthcare systems.
What Are the Clinical Uses of Rabeprazole?
Rabeprazole is prescribed for the treatment of duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD). It is also used in combination with antibiotics to eradicate Helicobacter pylori infection, a common cause of ulcers, and for the long-term management of conditions involving excessive stomach acid production, such as Zollinger-Ellison syndrome [1].
What is the Difference Between Rabeprazole and Other PPIs?
Rabeprazole belongs to the same class of drugs as omeprazole, lansoprazole, pantoprazole, and esomeprazole. While all PPIs share the same mechanism of action—inhibiting the proton pump—they may differ in their pharmacokinetic profiles, such as the speed of onset, duration of action, and metabolism. Rabeprazole is often noted for its rapid onset of action [1].
What Are the Side Effects of Rabeprazole?
Common side effects associated with rabeprazole include headache, diarrhea, nausea, abdominal pain, vomiting, and dizziness. Less common side effects can occur, and long-term use of PPIs has been associated with potential risks such as vitamin B12 deficiency, hypomagnesemia, and an increased risk of bone fractures. Patients should discuss any concerns about side effects with their healthcare provider [1].
---
Sources:
1. National Institutes of Health. (n.d.). Rabeprazole. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a603025.html
2. DrugBank. (n.d.). Rabeprazole Sodium. Retrieved from https://go.drugbank.com/drugs/DB00447
3. Varghese, S., et al. (2018). Synthesis and characterization of rabeprazole sodium and its related substances. International Journal of Pharmacy and Pharmaceutical Sciences, 10(7), 72-77.
4. DrugPatentWatch.com. (n.d.). Rabeprazole. Retrieved from https://drugpatentwatch.com/drugs/rabeprazole